Sanofi-Aventis 4Q Revenues: $8.3 billion (+7%) 4Q Earnings: $1.7 billion (+21%) FY Revenues: $32.5 billion (+8%) FY Earnings: $7.6 billion (+26%) Comments: R&D expenses were up 6.6% to $1.4 billion in the quarter and up 2% to $4.8 billion for the year, representing 15% of sales for the year. Results for the quarter and full-year are based on adjusted consolidated income and excludes the material impacts of purchase accounting for the Aventis acquisition and acquisition-r...